Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126697) titled 'Efficacy and Safety of Darolutamide Combined with Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer: A Multicenter, Prospective, Randomized Controlled Clinical Trial' on June 14.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

Condition: Prostate Cancer

Intervention: Experimental Group:Adopting the triple neoadjuvant treatment regimen of darolutamide + docetaxel + ADT

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-06-30

Target Sample Size: Ex...